Yahoo Finance

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal ...

- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy - Mutation agnostic potential of Actimab-A ...
Monthly Prescribing Reference

CLAG in Combination with Imatinib Mesylate Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia

SAN DIEGO, CA—Rami S. Komrokji, MD, from H. Lee Moffitt Cancer Center & Research Institute in Tampa, FL, and colleagues reported study data indicating that the CLAG regimen (cladribine, cytarabine, ...
ascopubs.org

Evaluation of the toxicity and outcomes of the combination of midostaurin and CLAG-M in patients with FLT3-mutated acute myeloid leukemia (AML): A multi-center retrospective ...

A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 ...
Nasdaq

Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that interim data from its ongoing Actimab-A CLAG-M Phase 1 ...
Finanznachrichten

Actinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid ...

The trial will optimize the dose of Actimab-A in combination with CLAG-M, that will be studied in the Phase 3 portion of the trial, which will be a randomized trial comparing overall survival and ...